The association between polycystic ovary syndrome (PCOS) and endometrial cancer remains unclear. We aimed to investigate the causal association between genetically predicted PCOS and endometrial cancer risk in two ethnic groups through a two-sample Mendelian randomization (MR) approach. Our study includes 13 single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) for PCOS in Europeans, and another 13 SNPs are used as IVs for PCOS in Asians. Outcome data were obtained from the largest published meta-GWAS of European ancestry to date, as well as from the BioBank Japan Project of Asian ancestry. Our study demonstrates that genetically predicted PCOS is not causally associated with the risk of overall endometrial cancer in either Europeans or Asians (odds ratio (OR) = 0.93, 95% confidence interval (CI) = 0.85–1.01, p = 0.09 and OR = 0.98, 95% CI 0.84–1.13, p = 0.75, respectively). Subgroup analyses according to histotype further illustrate that PCOS might not be associated with the risk of either endometrioid endometrial cancer or non-endometrioid endometrial cancer in European ancestry. No pleiotropy is found in our study, and a sensitivity analysis shows similar results. Our results indicate that genetically predicted PCOS might not be associated with the risk of endometrial cancer.

Keywords: polycystic ovary syndrome, endometrial cancer, Mendelian randomization, GWAS, SNP

INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most prevalent reproductive endocrine disorders affecting five to 10 percent of reproductive-aged women around the world, and it greatly influences patient quality of life, fertility and long-term health (1, 2). PCOS is an unexplained heterogeneous clinical syndrome that might be caused by a combination of genetic and environmental factors.
Due to the heterogeneity of PCOS, it is clinically diagnosed by multiple diverse diagnostic criteria according to the Androgen Excess and PCOS Society (3), the National Institutes of Health/ National Institute of Child Health and Human Disease (NIH/ NICHD) (4) and the European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) (Rotterdam criteria) (5). Although there is no consensus on the clinical definition of PCOS, it is well accepted that hyperandrogenism and oligo-ovulation are the main characteristics of PCOS (6). Women with PCOS are at higher risk for comorbidities, including obesity, hyperinsulinemia, insulin resistance (IR), metabolic disorders, infertility, endothelial dysfunction, cardiovascular disorders and the development of cancer. Previous studies have found that PCOS was associated with an increased risk of cancer in the endometrium, ovaries, endocrine glands, pancreas, kidneys and skeletal and hematopoietic system (7, 8).

Endometrial cancer, rising in both incidence and associated mortality, is a common gynecological tumor (9). It is well known that a family history of endometrial cancer, aging, obesity, unopposed estrogen exposure (from hormone replacement therapy and tamoxifen use, for example), never having given birth, early age at menarche and late-onset menopause are risk factors of endometrial cancer (10). The results, however, of epidemiologic studies regarding the association between PCOS and endometrial cancer remain inconclusive (11). Most of the prior studies are observational studies, the findings of which could have possibly been affected by confounding factors and reverse causality due to the study design. For instance, many studies failed to control body mass index (BMI), which is an important potential confounder correlated with both PCOS and endometrial cancer risk (1, 12), leading to inaccurate estimates of their association. Moreover, endometrial cancer is most commonly classified into two subtypes according to clinical and histological characteristics: Type I endometrial cancer, which is usually estrogen dependent, is a uterine endometrioid carcinoma. Type II endometrial cancer, which is estrogen independent, has a non-endometrioid histology including serous carcinoma, carcinosarcoma, clear cell carcinoma, mucinous carcinoma and mixed histology types (13). Different subtypes of endometrial cancer may have different etiological risk factors, but none of the previous studies have stratified their outcomes. Consequently, without further stratification, the measurement of the association between PCOS and the risk of endometrial cancer might be unclear and inaccurate.

MATERIALS AND METHODS

Genetic Instrumental Variables for PCOS

SNPs related to PCOS in Europeans were obtained from a GWAS meta-analysis that included 10,074 patients with PCOS and 103,164 health controls of European ancestry (18). In total, fourteen independent single nucleotide polymorphisms (SNPs) were estimated to be correlated to PCOS at the genome-wide significance level ($P < 5 \times 10^{-8}$). Of these SNPs, none were correlated ($r^2 < 0.001$) in linkage disequilibrium (LD) analysis; one palindromic variant (rs853854) was excluded because of an effect allele frequency (EAF) close to 50% (19). The F-statistic was calculated to avoid weak IV bias (20, 21), where IVs with F-statistics > 10 were considered as strong IVs. In the present study, all IVs were strong IVs; therefore, thirteen SNPs in total were included to construct the genetic IVs for PCOS in Europeans (Table 1).

We identified SNPs that were significantly related to PCOS in Asians from two PCOS GWAS datasets on cohorts of Han Chinese ancestry (22, 23). A GWAS consisting of 4082 PCOS cases and 6687 controls identified three independent SNPs that were strongly associated with PCOS (22). Another GWAS, including 10,480 cases and 10,579 controls, discovered ten independent SNPs were strongly associated with PCOS (22, 23). A GWAS consisting of 4082 PCOS cases and 6687 controls identified three independent SNPs that were strongly associated with PCOS (22). Another GWAS, including 10,480 cases and 10,579 controls, discovered ten independent SNPs were strongly associated with PCOS (22, 23). Eventually, thirteen independent SNPs were adopted as IVs for PCOS in Asians after checking for LD ($r^2 < 0.001$), palindromic SNP and weak IVs (Table 2).

GWAS on Endometrial Cancer

Genetic association data on endometrial cancer in Europeans was acquired from the largest published meta-GWAS of endometrial cancer to date, which includes a total of 12,906 endometrial cancer patients and 108,979 country-matched health participants of European ancestry from seventeen studies identified via the UK Biobank, the Endometrial Cancer Association Consortium (ECAC) and the Epidemiology of Endometrial Cancer Consortium (E2C2) (24). These endometrial cancer cases were further divided into an endometrioid histology group (8758 cases) and a non-endometrioid histology group (with serous carcinoma, carcinosarcoma, clear cell carcinoma or mucinous carcinoma) (1230 cases) according to the histological subtypes of endometrial cancer (24, 25). In this work, we extracted overall and histotype-specific endometrial cancer-specific beta coefficients and standard errors from the summary statistics of the meta-GWAS for each of the 13 SNPs for PCOS in Europeans.
TABLE 1 | PCOS SNPs used to construct the instrument variable in Europeans.

| Chr | Position | SNP   | Effect Allele | Other Allele | EAF  | Beta  | SE   | Gene     | P value |
|-----|----------|-------|---------------|--------------|-------|-------|------|----------|---------|
| 2   | 43561780 | rs7563201 | A       | G           | 0.4507 | -0.1081 | 0.0172 | THADA    | 3.68E-10 |
| 2   | 213391766 | rs2178575 | A       | G           | 0.1512 | 0.1663  | 0.0219 | ERBB4    | 3.34E-14 |
| 3   | 131813204 | rs13164856 | T       | C           | 0.7291 | 0.1325  | 0.0193 | IGF1/RAD50 | 1.45E-10 |
| 8   | 11623889  | rs804279  | A       | T           | 0.2616 | 0.1276  | 0.0184 | GATA4/NEIL2 | 3.76E-12 |
| 9   | 5446689   | rs10739076 | A       | C           | 0.3076 | 0.1097  | 0.0197 | PLGK1T    | 2.51E-08 |
| 9   | 97723266  | rs7864171 | A       | G           | 0.4284 | -0.0900 | 0.0168 | FANCC     | 2.95E-08 |
| 9   | 126619233 | rs9696009 | A       | G           | 0.0679 | 0.202   | 0.0311 | DENND1A   | 7.96E-11 |
| 10  | 30226366  | rs11031005 | T       | C           | 0.8537 | -0.1593 | 0.0223 | ARL14EP/FSH-B | 8.66E-13 |
| 11  | 102043240 | rs11225154 | A       | G           | 0.0941 | 0.1787  | 0.0272 | YAP1      | 5.44E-11 |
| 11  | 113949232 | rs1784692 | T       | C           | 0.8237 | 0.1438  | 0.0226 | ZBTB16    | 1.88E-10 |
| 12  | 56477694  | rs2271194 | A       | T           | 0.416  | 0.0971  | 0.0166 | ERBB3/RASB5 | 4.57E-09 |
| 12  | 75941042  | rs1795379 | T       | C           | 0.2398 | -0.1174 | 0.0195 | KRR1      | 1.81E-09 |
| 16  | 52375777  | rs9843703 | A       | T           | 0.815  | -0.1273 | 0.0208 | TOX3      | 9.61E-10 |

Chr, chromosome; SNP, single nucleotide polymorphism; EAF, effect allele frequency; SE, standard error.

TABLE 2 | PCOS SNPs used to construct the instrument variable in Asians.

| Chr | Position | SNP   | Effect Allele | Other Allele | EAF  | Beta  | SE   | Gene     | P value |
|-----|----------|-------|---------------|--------------|-------|-------|------|----------|---------|
| 2   | 43638838  | rs13429458 | A       | C           | 0.81  | 0.401  | 0.04  | THADA    | 1.73E-23 |
| 2   | 48978159  | rs13405728 | A       | G           | 0.754 | 0.343  | 0.037 | LHCGR    | 7.34E-11 |
| 2   | 49201612  | rs2268361 | C       | T           | 0.504 | 0.139  | 0.02   | FSHR     | 9.98E-13 |
| 2   | 49247832  | rs2349415 | T       | C           | 0.181 | 0.174  | 0.025 | FSHR     | 2.35E-12 |
| 9   | 97684587  | rs4385527 | G       | A           | 0.781 | 0.174  | 0.03  | C9orf3(AOPEP) | 5.87E-09 |
| 9   | 97741336  | rs3804257 | G       | A           | 0.904 | 0.261  | 0.036 | C9orf3(AOPEP) | 5.28E-14 |
| 11  | 126525212 | rs2479106 | G       | A           | 0.222 | 0.293  | 0.033 | DENND1A  | 8.12E-19 |
| 11  | 102070639 | rs1894116 | G       | A           | 0.194 | 0.239  | 0.024 | YAP1     | 1.08E-22 |
| 12  | 56390636  | rs705702  | G       | A           | 0.245 | 0.239  | 0.023 | RABSB/SUOX | 8.64E-26 |
| 12  | 6224461   | rs2220746 | A       | C           | 0.907 | 0.357  | 0.038 | HMGA2    | 1.95E-21 |
| 16  | 52347819  | rs4784165 | G       | T           | 0.325 | 0.14   | 0.021 | TOX3     | 3.64E-11 |
| 20  | 7166109   | rs2659807 | G       | A           | 0.301 | 0.131  | 0.023 | INSR     | 1.09E-08 |
| 20  | 52447300  | rs6022786 | A       | G           | 0.339 | 0.122  | 0.02  | SUMO1P1  | 1.85E-09 |

Chr, chromosome; SNP, single nucleotide polymorphism; EAF, effect allele frequency; SE, standard error.

Genetic association data on endometrial cancer in Asians were acquired from the BioBank Japan Project (BBJ), which includes 999 cases and 89,731 controls of Asian ancestry (26). BBJ recruited participants from 12 cooperating medical institutions in Japan. The identification of endometrial cancer cases was based on diagnoses by physicians at each hospital. Disease-specific laboratory examinations and imaging data were collected in BBJ (27), but these data did not include information about the histology of the endometrial cancer. Similarly, we extracted overall endometrial cancer–specific beta coefficients and standard errors from the GWAS summary level results for each of the 13 SNPs for PCOS in Asians.

Statistical Analysis

MR is a statistical method of using genetic variants related to a modifiable exposure to examine whether an observational effect between this specific exposure and the outcome is consistent with a causal association (14). To obtain a reliable understanding for MR analysis, three prerequisite assumptions must be satisfied (28): (a) the IVs are strongly associated with PCOS; (b) the IVs can only affect endometrial cancer through their effects on PCOS; (c) the IVs are independent of any confounding factors that may influence the association between PCOS and endometrial cancer. In this case, MR analysis is less susceptible to reverse causation and confounding factors, which may greatly influence the results of epidemiological observational studies.

We evaluated the association of PCOS with overall and histotype-specific endometrial cancer risk. MR analyses in Europeans and Asians were conducted using an IV consisting of 13 SNPs for PCOS in Europeans and a 13-SNP IV for PCOS in Asians, respectively. The inverse-variance weighted (IVW) method was carried out as a main method of MR analysis. Odds ratios (OR) and 95% confidence intervals (CIs) for overall endometrial cancer risk, as well as both subtypes of endometrial cancer risk, were estimated.

Regarding sensitivity analyses, MR-Egger regression, weighted median, simple mode and weighted mode methods were employed in our study to assess whether the IVs could affect endometrial cancer merely through their impact on PCOS. MR-Egger regression, a method for detecting small study reporting bias in meta-analysis, was adapted to assess bias from pleiotropic effects. As such, the beta coefficient from an Egger regression can provide a consistent estimate of any causal effect (29). The weighted median method is able to provide a consistent estimate of the finding if more than half of the weight is derived from valid IVs (30). The simple mode method can also provide a consistent estimate if the most common horizontal pleiotropy value is zero, regardless of the type of horizontal
pleiotropy. Also, the weighted mode method requires that the largest subset of instruments that demonstrates the same association is contributed by valid IVs (31). We also applied the MR-Pleiotropy Residual Sum and Outlier (MR-PRESSO) method to detect and correct horizontal pleiotropy and potential outliers (32). Finally, the heterogeneity of the association was also tested using Cochran’s Q test on the IVW and MR-Egger estimates.

We also carried out additional sensitivity analyses taking the potential confounders of endometrial cancer into account. It is well known that endometrial cancer has a strong association with obesity, high BMI and waist-to-hip ratio (WHR) (10, 33), all of which may increase the risk of PCOS (6, 34). Oral contraceptives (OCs), which have been widely accepted as a first line of treatment against PCOS, have also been found to be linked to a reduced risk of endometrial cancer (35). Additionally, parity may also be a potential confounding factor in this study because, on the one hand, it is known that PCOS is a major cause of female infertility (36), and, on the other hand, decreased parity is also shown to be associated with an increased risk of endometrial cancer (33).

We assessed whether PCOS-associated SNPs were correlated with the aforementioned potential confounders at a genome-wide significance level (P < 5.0×10⁻⁸) by searching through the Phenoscanner database (http://www.phenoscanner.medschl.cam.ac.uk) (37). Among individuals of European ancestry, we found that rs2271194 was significantly associated with BMI, whereas in Asian PCOS SNPs, we found that rs705702 was correlated with BMI. We also examined whether PCOS SNPs were in LD (r² > 0.2) with genome-wide significant signals for the following confounding factors: BMI, WHR, OC use and parity. Since there is no GWAS assessing OC use, we did not assess the association of included PCOS SNPs with OC and parity. Two European PCOS SNPs (rs9696009 and rs2271194) and two Asian PCOS SNPs (rs2479106 and rs705702) are linked to SNPs for increases in BMI, and one European PCOS SNP (rs7563201) and three Asian PCOS SNPs (rs13429458, rs2059807 and rs6022786) are linked to SNPs for increases in WHR (see Supplementary Table 1).

Thus, we conducted a series of sensitivity analyses in which a subset of PCOS SNPs, excluding SNPs associated with confounders, was used as IVs. In Europeans, we used the following groups of IVs: (a) eleven SNPs after removing two SNPs linked to BMI; (b) twelve SNPs after dismissing one SNP linked to WHR; (c) ten SNPs after discharging all three of these SNPs. In Asians, we used the following groups of IVs: (a) eleven SNPs after removing two SNPs linked to BMI; (b) ten SNPs after dismissing three SNPs linked to WHR; (c) eight SNPs after discharging all five of these SNPs. MR analyses and sensitivity analyses were performed in R (version 4.0.2) using the TwoSampleMR package (version 0.5.5) and the MR-PRESSO package (version 1.0).

**RESULTS**

The causal effect estimates of PCOS on endometrial cancer are displayed in Figure 1 and Supplementary Figure 1. In this study, we did not observe a significant association between genetically predicted PCOS and the risk of endometrial cancer in either European ancestry or Asian ancestry (OR = 0.93, 95% CI 0.85–1.01, p = 0.09 and OR = 0.98, 95% CI 0.84–1.13, p = 0.75, respectively). Subgroup analyses according to histotype indicate that PCOS is not significantly associated with the risk of either endometrioid endometrial cancer (OR = 0.96, 95% CI 0.87–1.05, p = 0.36) or non-endometrioid endometrial cancer (OR = 0.99, 95% CI 0.79–1.25, p = 0.94) in European ancestry.

In all cases, the MR-Egger and MR-PRESSO results are not statistically significant (p > 0.05), demonstrating an absence of directional pleiotropy (Table 3). In sensitivity analyses using the

**FIGURE 1** Causal effect estimates of PCOS on endometrial cancer: the inverse-variance weighted (IVW) method was applied as the primary method for MR analysis. Abbreviations: PCOS, polycystic ovary syndrome; IVS, instrumental variables; SNP, single nucleotide polymorphism; n, number (number of SNPs included in the analysis); b, beta coefficient; se, standard error; OR, odds ratio; CI, confidence interval; BMI, body mass index; WHR, waist-to-hip ratio.
SNPs related to BMI or WHR (OR = 0.91, 95% CI 0.83–0.99) risk of overall endometrial cancer in Europeans after removing Supplementary Table 2.

After excluding PCOS SNPs associated with WHR, however, our results show that genetically predicted PCOS is correlated to a reduced risk of overall endometrial cancer in European ancestry (OR = 0.91, 95% CI 0.84–0.99, p = 0.03). This association is absent in Asians and subgroup analyses according to histotype in Europeans (see Supplementary Table 3). Furthermore, PCOS is also associated with a reduced risk of overall endometrial cancer in Europeans after removing SNPs related to BMI or WHR (OR = 0.91, 95% CI 0.83–0.99, p = 0.03). Still, this association is absent in Asians and subgroup analyses in Europeans (Supplementary Table 4).

DISCUSSION

For the first time, our MR study evaluates the association between PCOS and endometrial cancer, and our findings suggest that PCOS is not causally related to the risk of endometrial cancer in either European or Asian ancestry.

Previously, numerous observational studies found controversial conclusions on whether the risk of endometrial cancer is associated with PCOS. One meta-analysis demonstrated that PCOS was associated with a higher risk of endometrial cancer in women with an assessed OR of 2.79 (95% CI 1.31–5.95) (38). All of the included studies, however, were of moderate or low quality because none of them adjusted their results for confounding factors, such as BMI, diabetes and inflammation. One study found that women with PCOS have a higher risk of endometrial cancer compared to their age-matched controls, regardless of BMI (ORunadjusted = 5.3, 95% CI 1.5–18.6 and ORadjusted = 6.1, 95% CI 1.0–36.9, respectively) (39). On the contrary, two studies found no relationship between PCOS and risk of endometrial cancer after adjusting for BMI (OR BMI-adjusted = 2.2, 95% CI 0.9–5.7 and OR BMI-adjusted = 1.3, 95% CI 0.7–2.2, respectively) (40, 41). The contradictory conclusions of these observational studies might have been caused by confounding factors. Thus, a major advantage of our study is that MR can control for the influence of confounding factors. Moreover, endometrial cancer has two main subtypes: endometrioid (Type I) and non-endometrioid (Type II). But only one study investigated the association between PCOS and the subtypes of endometrial cancer, reporting a slightly stronger relationship

| Outcomes | Number of SNPs | Beta | SE  | OR (95% CI) | P       | P for heterogeneity test | P for MR-Egger intercept | P for MR-PRESSO Global test |
|----------|----------------|------|-----|-------------|---------|--------------------------|--------------------------|-------------------------|
| Endometrial Cancer in Europeans | MR Egger | 13  | -0.04 | 0.218 | 0.961 (0.627 - 1.472) | 0.857 | 0.236 | 0.873 |
|  | Weighted median | 13  | -0.04 | 0.062 | 0.958 (0.849 - 1.081) | 0.489 |
|  | Inverse variance weighted | 13  | -0.075 | 0.044 | 0.928 (0.851 - 1.011) | 0.088 | 0.302 |
|  | Simple mode | 13  | -0.01 | 0.109 | 0.990 (0.799 - 1.227) | 0.928 |
|  | Weighted mode | 13  | -0.029 | 0.115 | 0.971 (0.775 - 1.217) | 0.805 |
|  | MR-PRESSO (raw, 0 outliers) | 13  | -0.058 | 0.045 | 0.944 (0.864 - 1.031) | 0.222 |
| Endometrioid Endometrial Cancer in Europeans | MR Egger | 13  | -0.12 | 0.23 | 0.887 (0.564 - 1.393) | 0.612 | 0.441 | 0.742 |
|  | Weighted median | 13  | -0.033 | 0.07 | 0.967 (0.843 - 1.109) | 0.632 |
|  | Inverse variance weighted | 13  | -0.044 | 0.048 | 0.957 (0.870 - 1.052) | 0.362 | 0.517 |
|  | Simple mode | 13  | -0.022 | 0.117 | 0.978 (0.778 - 1.230) | 0.854 |
|  | Weighted mode | 13  | -0.029 | 0.111 | 0.972 (0.781 - 1.208) | 0.800 |
|  | MR-PRESSO (raw, 0 outliers) | 13  | -0.018 | 0.051 | 0.982 (0.889 - 1.085) | 0.729 | 0.269 |
| Non-Endometrioid Endometrial Cancer in Europeans | MR Egger | 13  | 0.521 | 0.565 | 1.884 (0.557 - 5.905) | 0.376 | 0.449 | 0.358 |
|  | Weighted median | 13  | 0 | 0.162 | 1.000 (0.728 - 1.375) | 0.999 |
|  | Inverse variance weighted | 13  | -0.009 | 0.118 | 0.991 (0.786 - 1.250) | 0.941 | 0.457 |
|  | Simple mode | 13  | 0.041 | 0.286 | 1.042 (0.596 - 1.820) | 0.889 |
|  | Weighted mode | 13  | 0.035 | 0.292 | 1.036 (0.584 - 1.836) | 0.906 |
|  | MR-PRESSO (raw, 0 outliers) | 13  | -0.004 | 0.109 | 0.996 (0.804 - 1.233) | 0.973 | 0.505 |
| Endometrial Cancer in Asians | MR Egger | 13  | 0.01 | 0.204 | 1.010 (0.678 - 1.505) | 0.963 | 0.091 | 0.858 |
|  | Weighted median | 13  | -0.011 | 0.092 | 0.989 (0.826 - 1.185) | 0.907 |
|  | Inverse variance weighted | 13  | -0.024 | 0.077 | 0.976 (0.839 - 1.135) | 0.751 | 0.127 |
|  | Simple mode | 13  | -0.022 | 0.158 | 0.978 (0.717 - 1.335) | 0.893 |
|  | Weighted mode | 13  | -0.002 | 0.112 | 0.998 (0.801 - 1.242) | 0.983 |
|  | MR-PRESSO (raw, 0 outliers) | 13  | -0.0245 | 0.077 | 0.976 (0.839 - 1.135) | 0.756 | 0.132 |

SNP, single nucleotide polymorphism; SE, standard error; OR, odds ratio; CI, confidence interval.
between PCOS and Type I endometrial cancer (OR\textsuperscript{endometrioid} = 2.4, 95% CI 1.0–6.2) (41).

In our study, we did not find a significant association between PCOS and the risk of endometrial cancer. After removing SNPs associated with potential confounders and subgroup analyses according to histotype, our MR study concluded that PCOS still does not have any causal association with the risk of endometrial cancer. Although our results indicate that PCOS does not directly increase the risk of endometrial cancer, the obesity feature of PCOS has been found to be carcinogenic in numerous observational and MR studies (33, 42). The findings of increased BMI in PCOS women might explain the association between PCOS and the increased risk of endometrial cancer, especially in studies with no adjustment for BMI.

Our study contains several advantages. First, a major strength of this study is its two-sample MR design, which can prevent the influence of reverse causality and potential confounding factors. Second, the study’s IVs are derived from the latest and largest PCOS GWAS in Asians and Europeans (18, 22, 23), and our endometrial cancer data were obtained from the latest and biggest endometrial cancer GWAS in both ethnic groups (24, 26), which can thus better represent exposure and outcomes. Therefore, our study can provide sufficient statistical strength and precise estimates of causal effects. Third, we conducted sensitivity analyses for confounding factors and pleiotropy. Using MR Egger and MR-PRESSO analyses, we did not detect horizontal pleiotropy. In addition, we also assessed the impact of potential confounding factors, such as BMI and WHR (10). After removing SNPs associated with these potential confounders, our MR study suggests that genetically predicted PCOS still does not have any causal association with the risk of endometrial cancer, suggesting that there is no independent association between PCOS and endometrial cancer. Moreover, we stratified our outcomes based on the histotype of endometrial cancer, which was often neglected by previous observation studies. In our study, the inverse relationship between PCOS and overall endometrial cancer in Europeans after removing SNPs associated with (a) WHR and (b) WHR or BMI is diminished by subgroup analysis according to histotype, further revealing the negative association between PCOS and endometrial cancer. Nonetheless, our study still has several limitations. First, we found that PCOS is not related to endometrial cancer in two ethnic groups based on GWAS data summaries of European and Asian populations. Therefore, it is unclear whether our results are still applicable to other populations. Also, for the analysis in Asians, the selected IVs were based on a Chinese PCOS GWAS, and the outcomes were from a GWAS of Japanese endometrial cancer cases and controls. These two east Asian populations are not genetically identical, but they are genetically closely related and comparable. Studies have reported that the Han Chinese and Japanese ethnic groups show similar patterns for most genetic polymorphisms (43). But some researchers have also found that they are less similar regarding genome-wide variations (44), which may have influenced the accuracy of our study. Second, we did not assess the causal relationship between body weight, BMI, WHR and PCOS, as well as their causal association with endometrial cancer, because previous studies have already investigated these aspects and found that an increase in BMI is causally associated with PCOS and endometrial cancer risk (6, 42, 45, 46). Third, due to limited information, we were unable to verify that the PCOS-related SNPs we selected are related to individuals known for having PCOS in their outcome (i.e. endometrial cancer) databases. The lack of this control experiment decreases the rationality of our study because the association between genetics and clinics cannot be fully verified. Fourth, our study was not able to assess the association between each PCOS phenotype and the risk of endometrial cancer. In our study, the Asian GWAS for PCOS used Rotterdam criteria, whereas the European PCOS GWAS utilized the NIH/NICHD criteria (14.6%), self-reported diagnosis (51.4%) and also the Rotterdam criteria (34.0%) (18). This might affect the specificity of the European PCOS IVs. In 2012, the NIH consensus panel recommended the following clinical phenotype classification for PCOS: (a) Phenotype A consists of ovulatory dysfunction (OD), hyperandrogenism (HA) (clinical or biochemical) and polycystic ovaries (PCO); (b) Phenotype B consists of HA and OD; (c) Phenotype C consists of PCO and HA; (d) Phenotype D consists of PCO and OD (47). We failed, however, to stratify our outcomes according to the different clinical phenotypes of PCOS due to a lack of information and since we were not able to identify the risks of each phenotype of PCOS, which is quite significant in clinical practice. Further studies using different clinical phenotypes of PCOS are needed to fully explore the association between PCOS and endometrial cancer.

CONCLUSIONS

In conclusion, based on the MR results generated using data summaries from large-scale GWAS analyses, our observations suggest that genetically predicted PCOS is not related to a higher risk of endometrial cancer.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://www.repository.cam.ac.uk/handle/1810/289950, https://gwas.mrcieu.ac.uk/datasets/ and http://jenger.riken.jp/en/result.

AUTHOR CONTRIBUTIONS

Conceptualization: LQ, YW, HC, and YZ. Data curation and formal analysis: RG and KC. Funding acquisition: LQ. Software and visualization: HC, YZ, and YT. Supervision: SL, WX, and YY. Writing of the original draft: HC and YZ. Review and editing: LQ and YW. HC and YZ verified the underlying data. All authors contributed to the article and approved the submitted version.
from the Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.756137/full#supplementary-material

Supplementary Figure 1 | Scatter plot of PCOS on endometrial cancer: (A) scatter plot of PCOS on endometrial cancer in Asians; (B) scatter plot of PCOS on overall endometrial cancer in Europeans; (C) scatter plot of PCOS on endometroid endometrial cancer in Europeans; (D) scatter plot of PCOS on non-endometroid endometrial cancer in Europeans.

REFERENCES

1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic Ovary Syndrome. Nat Rev Dis Primers (2016) 2:16057. doi: 10.1038/nrdp.2016.57
2. Escobar-Morreale HF. Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment. Nat Rev Endocrinol (2018) 14(5):270–84. doi: 10.1038/nrendo.2018.24
3. Azziz R, Carmina E, Dewsall D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab (2006) 91(11):4237–45. doi: 10.1210/jc.2006-0178
4. Zawadzski JK, Dunaif A. Diagnostic Criteria for Polycystic Ovary Syndrome: Towards a Rational Approach. In: Dunaif A, Givens JR, Haslinie F. Polycystic Ovary Syndrome Boston: Blackwell Scientific (1992). 377–84.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. Fertil Steril (2004) 81(1):19–25. doi: 10.1016/j.fertnstert.2003.10.004
6. Brower MA, Hai Y, Jones MR, Guo X, Chen Y-DI, Rotter JI, et al. Bidirectional Mendelian Randomization to Explore the Causal Relationships Between Body Mass Index and Polycystic Ovary Syndrome. Hum Reprod (Oxford England) (2019) 34(1):127–36. doi: 10.1093/humrep/dey343
7. Yin W, Falconer H, Yin L, Xu L, Ye W. Association Between Polycystic Ovary Syndrome and Cancer Risk. JAMA Oncol (2019) 5(1):106–7. doi: 10.1001/ jamaoncol.2018.5188
8. Naninck EFG, Stijger PC, Brouwer-Brolsma EM. The Importance of Maternal Folate Status for Brain Development and Function of Offspring. Adv Nutr (Bethesda Md) (2019) 10(3):502–19. doi: 10.1093/advnut/myz120
9. Segel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
10. Lu KH, Broadus RR. Endometrial Cancer. New Engl J Med (2020) 383(21):2053–64. doi: 10.1056/NEJMra1514010
11. Ignatov A, Ortman O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (2020) 12(3):1766. doi: 10.3390/cancers12071766
12. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial Cancer. Lancet (London England) (2016) 387(10023):1094–108. doi: 10.1016/s0140-6736(13)60130-0
13. Nakayama K, Nakayama N, Ishikawa M, Miyazaki K. Endometrial Serous Carcinoma: Its Molecular Characteristics and Histology-Specific Treatment Strategies. Cancers (2012) 4(3):799–807. doi: 10.3390/cancers 4030799
14. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA (2017) 318(19):1925–6. doi: 10.1001/jama.2017.17219
15. Pierce BL, Burgess S. Efficient Design for Mendelian Randomization Studies: Subsample and 2-Sample Instrumental Variable Estimators. Am J Epidemiol (2013) 178(7):1177–84. doi: 10.1093/aje/kwt084
16. Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Rissh HA, et al. Association Between Genetically Predicted Polycystic Ovary Syndrome and Ovarian Cancer: A Mendelian Randomization Study. Int J Epidemiol (2019) 48(3):822–30. doi: 10.1093/ije/dyz213
17. Wen Y, Wu X, Peng H, Li C, Jiang Y, Su Z, et al. Breast Cancer Risk in Patients With Polycystic Ovary Syndrome: A Mendelian Randomization Analysis. Breast Cancer Res Treat (2020) 185(3):799–806. doi: 10.1007/s10549-020-05973-9
18. Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, et al. Large-Scale Genome-Wide Meta-Analysis of Polycystic Ovary Syndrome Suggests Shared Genetic Architecture for Different Diagnosis Criteria. PLoS Genet (2018) 14(12):e1007813. doi: 10.1371/journal.pgen.1007813
19. Hartwig FP, Davies NM, Hennani G, Davey Smith G. Two-Sample Mendelian Randomization: Avoiding the Downsides of a Powerful, Widely Applicable But Potentially Fallible Technique. Int J Epidemiol (2016) 45(6):1717–26. doi: 10.1093/ije/dyx028
20. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the Suitability of Summary Data for Two-Sample Mendelian Randomization Analyses Using MR-Egger Regression: The Role of the I2 Statistic. Int J Epidemiol (2016) 45(6):1961–74. doi: 10.1093/ije/dyw220
21. Burgess S, Thompson SG. Avoiding Bias From Weak Instruments in Mendelian Randomization Studies. Int J Epidemiol (2011) 40(5):755–64. doi: 10.1093/ije/dyr036
22. Chen Z-J, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-Wide Association Study Identifies Susceptibility Loci for Polycystic Ovary Syndrome on Chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet (2011) 43(1):55–9. doi: 10.1038/ng.732
23. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-Wide Association Study Identifies Eight New Risk Loci for Polycystic Ovary Syndrome. Nat Genet (2012) 44(9):1020–5. doi: 10.1038/ng.2384
24. O’Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, et al. Identification of Nine New Susceptibility Loci for Endometrial Cancer. Nat Commun (2018) 9(1):3166. doi: 10.1038/s41467-018-05427-7
25. Cheng TH, Thompson DJ, O’Mara TA, Painter JN, Glubb DM, Flach S, et al. Five Endometrial Cancer Risk Loci Identified Through Genome-Wide Association Analysis. Nat Genet (2016) 48(6):667–74. doi: 10.1038/ng.3562
26. Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, et al. Large-Scale Genome-Wide Association Study in a Japanese Population Identifies Novel Susceptibility Loci Across Different Diseases. Nat Genet (2020) 52(7):679–9. doi: 10.1038/s41588-020-0640-3
27. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, et al. Overview of the BioBank Japan Project: Study Design and Profile. J Epidemiol (2017) 27(3S):S2–8. doi: 10.1093/je.2016.12.005
28. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological Challenges in Mendelian Randomization. Epidemiology (2014) 25(3):427–35. doi: 10.1097/EDE.0000000000000081
29. Bowden J, Davey Smith G, Burgess S. Mendelian Randomization With Invalid Instruments: Effect Estimation and Bias Detection Through Egger Regression. Int J Epidemiol (2015) 44(2):512–25. doi: 10.1093/ije/dyv080
30. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization With Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* (2016) 40(4):308–14. doi: 10.1002/gepi.21965

31. Hartwig FP, Davey Smith G, Bowden J. Robust Inference in Summary Data Mendelian Randomization via the Zero Modal Pleiotropy Assumption. *Int J Epidemiol* (2017) 46(6):1985–98. doi: 10.1093/ije/dyx102

32. Verbanck M, Chen CY, Neale B, Do R. Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred From Mendelian Randomization Between Complex Traits and Diseases. *Nat Genet* (2018) 50(5):693–8. doi: 10.1038/s41588-018-0099-7

33. Raglan O, Kalliala I, Markoziannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk Factors for Endometrial Cancer: An Umbrella Review of the Literature. *Int J Cancer* (2019) 145(7):1719–30. doi: 10.1002/ijc.31961

34. Ahn Y, Lee H, Cho YS. Identification of Genetic Variants for Female Obesity and Evaluation of the Causal Role of Genetically Defined Obesity in Polycystic Ovarian Syndrome. *Diabetes Metab Syndr Obes* (2020) 13:4311–22. doi: 10.2147/ dmso.S281529

35. Collaborative Group on Epidemiological Studies on Endometrial Cancer. *Polycystic Ovary Syndrome: Results of a 31 Year Follow-Up Study. Hormone-Related Factors and Gynecological Conditions in Relation to Cancer in Women With Polycystic Ovary Syndrome*. *Hum Reprod Update* (2014) 20(5):748–58. doi: 10.1093/humupd/dmu012

36. Hart R. PCOS and Infertility. *Pinnminerva Med* (2008) 50(4):305–14.

37. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. *PhenoScanner: A Database of Human Genotype-Phenotype Associations. Bioinformatics* (2016) 32(20):3207–9. doi: 10.1093/bioinformatics/btw373

38. Barry JA, Azizia MM, Hardiman PJ. Risk of Endometrial, Ovarian and Breast Cancer in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. *Hum Reprod Update* (2014) 20(5):748–58. doi: 10.1093/ humupd/dmu012

39. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-Term Consequences of PCOS and Infertility. *Hum Reprod* (2000) 15(2):101–5. doi: 10.1093/humrep/6.2.101

40. Zucchetto A, Serraino D, Polesel J, Negri E, De Paoli A, Dal Maso L, et al. *Diabetes Metab Syndrome* (2016) 10(6):dgaa125. doi: 10.1158/1055-9965.Epi-16-0147

41. Hart R. PCOS and Infertility. *PhenoScanner: A Database of Human Genotype-Phenotype Associations. Bioinformatics* (2016) 32(20):3207–9. doi: 10.1093/bioinformatics/btw373

42. Stoneking M, Delfin F. The Human Genetic History of East Asia: Weaving a Complex Tapestry. *Curr Biol* (2010) 20(4):R188–93. doi: 10.1016/j.cub.2009.11.052

43. Wang Y, Lu D, Chung YJ, Xu S. Genetic Structure, Divergence and Admixture of Han Chinese, Japanese and Korean Populations. *Hereditas* (2018) 155:19. doi: 10.1186/s41065-018-0057-5

44. Zhao Y, Xu Y, Wang X, Xu L, Chen J, Gao C, et al. *Body Mass Index and Polycystic Ovary Syndrome: A 2-Sample Bidirectional Mendelian Randomization Study. J Clin Endocrinol Metab* (2020) 105(6):dgaa125. doi: 10.1210/clinem/dgaa125

45. Zhao Y, Xu Y, Wang X, Xu L, Chen J, Gao C, et al. Body Mass Index and Polycystic Ovary Syndrome: A 2-Sample Bidirectional Mendelian Randomization Study. *J Clin Endocrinol Metab* (2020) 105(6):dgaa125. doi: 10.1016/clinem/dgaa125

46. Masuda T, Ogawa K, Katami Y, Murakami Y, Kimura T, Okada Y. A Mendelian Randomization Study Identified Obesity as a Causal Risk Factor of Uterine Endometrial Cancer in Japanese. *Cancer Sci* (2020) 111(12):4646–51. doi: 10.1111/cas.14667

47. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilo-Maradorn L, Azziz R. Criterio, Prevalence, and Phenotypes of Polycystic Ovary Syndrome. *Fertil Steril* (2016) 106(1):6–15. doi: 10.1016/j.fertnstert.2016.05.003

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chen, Zhang, Li, Tao, Gao, Xu, Yang, Cheng, Wang and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.